MedTrace Logo

Virological and Immunological Monitoring in Patients (suspected Of/confirmed With) COVID-19

NCT04904692 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 109

Last updated 2024-09-19

No results posted yet for this study

Summary

This study is a prospective, observational multicentric study. The study population entails adult patients hospitalized with a high clinical suspicion of COVID-19 and consists of two study arms (SARS-CoV2- vs. SARS-CoV2+).This combined fundamental research project has a dual goal: on the one hand assessing immunological predisposing factors for severe infection and investigating the immunological impact of SARS-CoV2 infection, on the other hand studying viral characteristics. Furthermore, a substudy will examine the pharmacokinetics and pharmacodynamics of hydroxychloroquine in patients receiving this antiviral treatment (REVIVE susbstudy). To answer these research questions, samples will be collected from patients with a high clinical suspicion of COVID-19, hospitalized at UZ Gent and 2 participating hospitals in Ghent (AZ Maria Middelares en AZ Jan Palfijn).

Conditions

Interventions

PROCEDURE

Blood draw

8x9mL EDTA tubes. In subjects treated with hydroxychloroquine treatment an extra EDTA tube (4mL) will be collected for the REVIVE substudy.

PROCEDURE

Bronchoalveolar lavage

Only in case of diagnostic or therapeutic indication.

PROCEDURE

SARS CoV-2 swabs

Nasopharyngeal, oropharyngeal and nasal swabs

Sponsors & Collaborators

  • Fund for Scientific Research, Flanders, Belgium

    collaborator OTHER

  • Chan Zuckerberg Initiative

    collaborator OTHER

  • Flanders Institute for Biotechnology

    collaborator UNKNOWN

  • University Hospital, Ghent

    lead OTHER

Principal Investigators

  • Linos Vandekerckhove, Prof. MD · University Hospital, Ghent

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-23
Primary Completion
2020-07-23
Completion
2024-09-30

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04904692 on ClinicalTrials.gov